News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,228 Results
Type
Article (39739)
Company Profile (248)
Press Release (660241)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204188)
Career Advice (2008)
Deals (35421)
Drug Delivery (95)
Drug Development (81053)
Employer Resources (172)
FDA (16189)
Job Trends (14864)
News (345230)
Policy (32547)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49444)
ALS (96)
Alzheimer's disease (1385)
Antibody-drug conjugate (ADC) (133)
Approvals (16187)
Artificial intelligence (265)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (80)
Brain cancer (27)
Breast cancer (293)
Cancer (2328)
Cardiovascular disease (180)
Career advice (1677)
Career pathing (30)
CAR-T (159)
Cell therapy (443)
Cervical cancer (20)
Clinical research (66105)
Collaboration (859)
Company closure (2)
Compensation (572)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (252)
Cystic fibrosis (102)
Data (2353)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6384)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (121)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (98)
Earnings (87151)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112700)
Executive appointments (746)
FDA (17579)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (777)
Gene editing (109)
Generative AI (20)
Gene therapy (318)
GLP-1 (720)
Government (4432)
Grass and pollen (4)
Guidances (169)
Healthcare (18820)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (143)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (99)
Interviews (312)
IPO (16530)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (326)
Lymphoma (159)
Machine learning (9)
Management (58)
Manufacturing (329)
MASH (78)
Medical device (13389)
Medtech (13394)
Mergers & acquisitions (19473)
Metabolic disorders (710)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (95)
Neuropsychiatric disorders (27)
Neuroscience (1949)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (40)
Obesity (372)
Opinion (205)
Ovarian cancer (81)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (154)
Partnered (22)
Patents (245)
Patient recruitment (116)
Peanut (46)
People (57357)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20600)
Phase II (29119)
Phase III (21676)
Pipeline (1432)
Policy (147)
Postmarket research (2563)
Preclinical (8764)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (386)
Real estate (5907)
Recruiting (65)
Regulatory (22332)
Reports (48)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (133)
Series B (91)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (51)
The Weekly (30)
Vaccines (699)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (201)
Last 7 days (959)
Last 30 days (3353)
Last 365 days (32518)
2025 (12124)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31481)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37886)
Australia (6195)
California (6482)
Canada (2077)
China (539)
Colorado (275)
Connecticut (282)
Delaware (159)
Europe (81435)
Florida (963)
Georgia (217)
Idaho (57)
Illinois (549)
India (25)
Indiana (323)
Iowa (11)
Japan (173)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (927)
Massachusetts (4812)
Michigan (226)
Minnesota (406)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1803)
New Mexico (28)
New York (1821)
North Carolina (993)
North Dakota (8)
Northern California (2871)
Ohio (210)
Oklahoma (14)
Oregon (34)
Pennsylvania (1438)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (26)
South Dakota (1)
Southern California (2433)
Tennessee (107)
Texas (962)
United States (24221)
Utah (188)
Virginia (153)
Washington D.C. (64)
Washington State (569)
West Virginia (3)
Wisconsin (58)
700,228 Results for "sientra inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
Sientra, Inc. announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on February 12, 2024.
February 13, 2024
·
6 min read
Biotech Beach
Sientra to Present at the Stifel 2023 Healthcare Conference
Sientra, Inc. today announced its participation at the Stifel 2023 Healthcare Conference.
November 8, 2023
·
1 min read
Business
Sientra Reports Third Quarter Financial and Operational Results
Sientra, Inc., a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, announced its financial results for the third quarter that ended September 30, 2023.
November 9, 2023
·
18 min read
Business
Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook
Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023.
October 30, 2023
·
8 min read
Business
Sientra Reports Record Second Quarter Financial and Operational Results
Sientra, Inc., a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, announced its financial results for the second quarter that ended June 30, 2023.
August 10, 2023
·
18 min read
Biotech Beach
Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 30, 2023
Sientra, Inc. announced that on June 27, 2023, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 20 new employees.
June 30, 2023
·
4 min read
Business
Sientra Announces Appointment of Alexander W. Casdin to Board of Directors
Sientra, Inc. announced the appointment of Alexander W. Casdin to the Company’s Board of Directors, effective June 15, 2023.
June 20, 2023
·
6 min read
FDA
Sientra Announces FDA-Clearance of Novel Portfinder™ Technology
Sientra, Inc. announced that the Food and Drug Administration (FDA) has granted a 510(k) clearance for the Company’s novel Portfinder™ technology.
May 17, 2023
·
5 min read
Business
Sientra to Report Second Quarter 2023 Financial Results on August 10, 2023
Sientra, Inc., a medical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, announced that it will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023.
July 27, 2023
·
1 min read
Biotech Beach
Sientra Announces FDA-Clearance of Next Generation AlloX2 Pro™ Tissue Expander
Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that the Food and Drug Administration (FDA) has granted a 510k-clearance for the Company’s novel, patented1 AlloX2 Pro Tissue Expander.
June 8, 2023
·
6 min read
1 of 70,023
Next
